DGX — Quest Diagnostics Incorporated

Momentum is strong: Q2 2026 revenue grew 10.2% YoY to $3.04B, adjusted EPS of $3.12 beat by $0.30, and FY26 guidance was raised to $11.95-$12.05B revenue and $11.05-$11.25 adjusted EPS. The Alzheimer's AD-Detect expansion with Roche's pTau217 test, NYS clearance of Haystack MRD, and multiple sell-side target hikes to $250-$260 have reinforced the bullish tone.

The trend is clearly inflecting upward. Revenue climbed from $2.40B in Q2 2024 to $2.76B in Q2 2025 to $3.04B in Q2 2026, with organic growth around 10% in the latest quarter. EPS has followed: $2.04 in Q2 2024, $2.47 in Q2 2025, $2.84 in Q2 2026. Operating margin is range-bound near 13-15% rather than structurally expanding, but Q2 2026's ~15.1% margin is solidly in the upper end of that range. This is a multi-quarter acceleration, not a one-quarter blip.

Expensive versus its own history. TTM P/E is 25.64 against a 5-year average of 17.44, forward P/E is roughly 21.9x FY26E EPS of $11.19, and P/S of 2.34 compares to a 5-year average of 1.79. The PEG of 2.03 also flags that the multiple is running ahead of sustainable growth. Some premium is justified by 10% organic growth and strong FCF, but the valuation is not cheap.

The market is paying up for continued execution: roughly 22x forward earnings for a company whose own historical average is closer to 17x. That works if low-double-digit organic growth and stable margins persist, but it leaves no cushion. If growth slows to mid-single digits or margins slip, a reversion toward 18-19x forward earnings would put fair value in the $200-$215 range rather than $245.

As of 2026-08-27, RSI(14) stood at 73.17, which is overbought. Price was +2.52% above the 20-day SMA, +9.86% above the 50-day SMA, and +22.61% above the 200-day SMA - a strong but extended uptrend. Entry-timing implication: chasing at $244.61 carries above-average short-term pullback risk; a pause or consolidation toward $230-$235 would offer better technical entry.

• Resilient demand for routine and advanced outpatient diagnostics is offsetting broader macro uncertainty.
• Wage inflation is being partially offset by lab automation and AI-driven productivity gains.
• Elevated interest rates and a debt-to-equity ratio of 0.85 make the balance sheet a modest watch item.
• Healthcare sector rotation toward defensive, cash-generative growers has helped drive DGX's multiple expansion.

• Q3 2026 earnings expected late October 2026; consensus is modeling EPS near $2.82, so another beat/raise would reinforce momentum.
• CEO fireside chat at the Baird Global Healthcare Conference on September 15, 2026, could provide color on Alzheimer's/MRD opportunities.
• Roche Elecsys pTau217 plasma test integration into the AD-Detect portfolio could open a new high-value testing growth stream.

• Reimbursement and pricing pressure from Medicare and commercial payors could compress margins.
• Rich valuation leaves limited room for error; any guidance cut or growth deceleration could trigger meaningful multiple compression.
• Higher debt levels and refinancing costs could pressure FCF if rates stay elevated.

Quest is a well-run business with clear momentum: 10% organic growth, raised guidance, a negative accruals ratio, and ~4.5% TTM FCF yield. The problem is price. At $244.61 the market already capitalizes continued strong execution, so the risk/reward is balanced rather than compelling. I would be more interested after a pullback toward $225-$230 or after Q3 confirms the upgraded trajectory.

Applied a 20.0x forward P/E - a justified premium to DGX's 17.4x five-year average but below the current ~21.9x forward multiple - to FY26E EPS of $11.19, yielding approximately $224. This rewards the 10% organic growth and ~4.5% FCF yield without paying up for the recent momentum or fully crediting the Alzheimer's/MRD optionality.